In the BioHarmony Drug Report Database

"Preview" Icon

Ravulizumab-cwvz

Ultomiris (ravulizumab) is an antibody pharmaceutical. Ravulizumab was first approved as Ultomiris on 2018-12-21. It is used to treat atypical hemolytic uremic syndrome in the USA. It has been approved in Europe to treat paroxysmal hemoglobinuria. It is known to target complement C5.

 

Trade Name

 

Ultomiris
 

Common Name

 

ravulizumab
 

ChEMBL ID

 

CHEMBL3989986
 

Indication

 

atypical hemolytic uremic syndrome, paroxysmal hemoglobinuria
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Ravulizumab-cwvz structure rendering